Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates
ALLOAllogene Therapeutics(ALLO) Zacks Investment Research·2024-03-15 06:16

Allogene Therapeutics (ALLO) came out with a quarterly loss of 0.43pershareversustheZacksConsensusEstimateofalossof0.43 per share versus the Zacks Consensus Estimate of a loss of 0.47. This compares to loss of 0.66pershareayearago.Thesefiguresareadjustedfornon−recurringitems.Thisquarterlyreportrepresentsanearningssurpriseof8.510.66 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 8.51%. A quarter ago, it was expected that this immuno- oncology company would post a loss of 0.53 per share when it actually produced a loss of $0.37, delivering a surprise of 30.19%. Over the last four quarters, ...